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Abstract 
Background : To compare magnesium sulfate with 
placebo in term neonates with moderate to severe 
ischemic encephalopathy due to severe perinatal 
asphyxia in term of improved neurological outcome. 
Methods: In this  randomized controlled trial a 
total of seventy term neonates of age less than six 
hours of either sex suffering  from moderate and 
severe hypoxic ischemic encephalopathy were 
included. Neonates were assessed at two different  
ages , 2-3 hours and 4-5 hours, respectively. Each 
patient remained in the hospital for at least 14 days.  
Patients were randomly divided into two groups A 
and B. Group A received magnesium sulphate at 250 
mg/kg/dose ( 1 ml/kg/ dose in 20 ml of 5% dextrose  
water) over one hour  with the additional  doses 
repeated at interval of 24 hours and 48 hours. Group 
B received 1 ml/kg/dose of normal saline in 20 ml of 
5% dextrose water. (Three doses , 24 hours apart). 
Serum magnesium levels were carried out  at seventy 
two hours of life.  .Monitoring was also done for 
clinical course of encephalopathy, laboratory 
variables and adverse effects. At the time of 
discharge ,neurological examination was carried out 
and CT scan was done at fourteenth day of life.    
Results:- More infants in group A were sucking at 
discharge as compared to group B (71.4℅ vs 40℅; 
p=0.008). Neuroimaging (CT scan on day 14th) 
yielded abnormal findings for fewer neonates in 
group A which was significantly low as compared to 
group B (11.4% vs 37.1℅ p= 0.012).  
Conclusion: Postnatal magnesium sulfate infusion 
is effective in improving outcome for infants with 
severe perinatal asphyxia.  
Key Words: Perinatal asphyxia, Magnesium 
sulfate, Ischemic encephalopathy 
 
Introduction 
Perinatal asphyxia is the fifth largest cause of child 
death. Perinatal asphyxia with metabolic acidosis in 
the cord blood may be followed by a moderate or 
severe neonatal encephalopathy. Magnesium is a 
naturally occurring N-methyl D-Aspartate(NMDA) 
receptor antagonist that blocks neuronal influx of 
calcium within the ionic channel. 1  In developed 
countries, perinatal asphyxia occurs in 1 to 1.5% of the 
live births. In developing countries, like India, the 
incidence of perinatal asphyxia was 5%, in different 
studies conducted in 16 different medical institutions.  
Severe perinatal asphyxia leads to encephalopathy in 
50 to 60% of the neonates. Neurological abnormality at 
discharge was found to be predictive of long term 
neuro-developmental delay.2 Perinatal asphyxia with 
metabolic acidosis in the cord blood (pH<7and base 
deficit >12mmo/L) may be followed by a moderate or 
severe neonatal encephalopathy within 24 hrs and 
further neurological impairment characterized by 
spastic quadriplegia and dyskinesia /dystonia.3 
In the CNS, inotropic glutamate receptors are the 
major excitatory neurotransmitter receptors that 
mediate almost all excitatory synaptic transmission in 
brain. Neuronal injuries like cerebral hypoxic ischemic 
encephalopathy are due to the overstimulation of 
NMDA receptors of glutamate type. Glutamate acts on 
the N-methyl-d-aspartate receptors, a postsynaptic 
channel in brain. High concentration of glutamate 
open NMDA channels, allowing excessive calcium 
influx into the neurons, inducing reversible neuronal 
injury.4 Magnesium is a naturally occurring NMDA 
receptor antagonist that blocks neuronal influx of 
calcium within the ionic channel.2 
A neuroprotective effect of magnesium sulfate has 
been shown in some animal models of perinatal 
hypoxic-ischemic brain damage.5 A study carried out 
in India  showed that postnatal magnesium sulfate  
treatment improved neurological outcome at discharge 
for term neonates with severe perinatal asphyxia. 
Neuroimaging (CT scan on day 14th) yielded abnormal 
findings for fewer neonates in the treatment group as 
compared to placebo group (16 ℅ vs. 44℅).Infants in 
treatment group were more likely to be sucking at 
discharge than those in placebo group (77℅ vs. 37℅). 
Good short term outcomes at discharge occurred for 
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77% of the patients in treatment group as compared 
with the placebo group.2  
In our setup magnesium sulfate is not routinely used 
as treatment option in severe birth asphyxia. This 
study is being carried out to find out the effectiveness 
of this drug, on the neurological outcome of term 
neonates, with severe perinatal asphyxia.  
Patients and Methods  
In this randomized controlled trial, carried out for six 
months (January-July 2013) in the department of 
Paediatrics Holy  Family Hospital, Rawalpindi, a total 
of seventy term neonates of age less than six hours of 
either sex suffering  from moderate and severe 
hypoxic ischemic encephalopathy were included in 
this study. Neonates were assessed at two different  
ages , 2-3 hours and 4-5 hours, respectively. Each 
patient remained in the hospital for at least fourteen 
days.  Patients were randomly divided into two 
groups A and B. Group A(n=35) received magnesium 
sulphate at 250 mg/kg/dose ( 1 ml/kg/ dose in 20 ml 
of 5% dextrose  water) over one hour  with the 
additional  doses repeated at interval of 24 hours and 
48 hours. Group B (n=35) received 1 ml/kg/dose of 
normal saline in 20 ml of 5% dextrose water. (Three 
doses , 24 hours apart). Serum magnesium levels were 
carried out  at seventy two hours of life. Monitoring 
was also done for clinical course of encephalopathy, 
laboratory variables and adverse effects. At the time of 
discharge ,neurological examination was carried out 
and CT scan was done at fourteenth day of life.Severe 
perinatal asphyxia was characterized by the history of 
fetal distress,need of immediate ventilation with a bag 
and mask or through ETT >2 min after delivery,5 
minute APGAR score of <6 minutes and base deficit of 
>15 mEq/L or pH of <7 in arterial blood gases after 
birth. Moderate or severe Hypoxic Ischemic 
Encephalopathy (HIE) was established when one or 
more sign is present in three of the six categories, i.e., 
level of consciousness, spontaneous 
activity,tone,posture,primitive reflexes and autonomic 
nervous system in terms of pupils , heart rate and 
breathing pattern. Exclusion criteria included severe 
intrauterine growth retardation, any condition 
unrelated to asphyxia, age  more than 6 hrs at 
admission, parental administration of magnesium to 
mother perinatally, chromosomal anomalies and 
congenital malformation 
Frequencies and percentages were calculated for 
qualitative variables for good neurological outcome 
that is, presence of suck reflex and the CT scan 
findings of the head. Chi Square test was used to 
determine the difference in outcome, in term of 
frequencies of both variables, in two groups. P-value 
of<0.05 was considered significant. Stratification was 
done to control effect modifiers like age and gender to 
observe an outcome Chi-square test was also used. 
p≤0.05 was considered as significant for each stratified 
data.  
Results 
The average age of the neonates was 3.56±0.82 hours 
in group A  and 3.58±0.73 in group B (Table 1). Out of 
70 neonates, 48(68.6%) were male and 22(31.4%) 
female.Moderate hypoxic ischemic encephalopathy 
was observed in 58.6% and severe hypoxic ischemic 
encephalopathy in 41.4% . Significant difference was 
not observed between groups in grade of hypoxic 
ischemic encephalopathy (p=0.225) (Table 2).Postnatal 
magnesium  sulfate treatment improved neurological 
outcome at discharge for term neonates with moderate 
to severe perinatal asphyxia. More infants in group A 
were sucking at discharge as compared to group B 
(71.4℅ vs 40℅; p=0.008) (Table 3). Neuroimaging (CT 
scan on day 14th) yielded abnormal findings for fewer 
neonates in group A, as compared to group B (11.4% 
vs 37.1℅ p= 0.012) (Table 4).Sucking at discharge was 
high in group A but it was not statistically significant 
between groups (p=0.16) while for 4 to 5 hours age 
infant sucking was significantly high in group A as 
compared to group B (p=0.019)(Table 5 ). Similarly 
neuroimaging (CT scan on day 14th) yielded abnormal 
findings for fewer neonates in group A as compared to 
group B for 2 to 3 hours age infant, (p= 0.015) while for 
4 to 5 hours age infants significant difference was not 
observed (Table 6 ).  In neurological outcome suck 
reflex was better in group A as compared to group B 
(Table 7). CT scan, performed at 14th day revealed 
pronounced findings in group B as compared to group 
A (Table 8).   
Table 1:Descriptive statistics of age and 
gestational age 
Variables Statistics Group A 
n=35 
Group B 
n=35 
Age of neonate (hours) Mean ± SD 3.56±0.82 3.58±0.73 
Gestational Age 
(Weeks) 
Mean ± SD 38.59±0.78 38.78±1.09 
Interquartile Range 1 1 
Table 2:Grade of hypoxic ischemic 
encephalopathy with respect to groups 
Grade of hypoxic  ischemic 
encephalopathy 
Group 
A(n=35) 
Group B 
n=35 
Total 
n=70 
Moderate 18(51.4%) 23(65.7%) 41(58.6%) 
Severe 17(48.6%) 12(34.3%) 29(41.4%) 
Chi-Square= 1.47  p=0.225 
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Table 3:Comparison of neurological outcome in 
term of suck reflex at the time of discharge  
 
Suck Reflex  
at discharge 
 
Group A 
n=35 
Group B 
n=35 
Total 
n=70 
Yes 25(71.4%) 14(40%) 39(55.7%) 
No 10(28.6%) 21(60%) 31(44.3%) 
Chi-Square= 7.006  p=0.008 
 
Table 4:Comparison of neurological outcome 
 in term of changes in CT scan at 14th day  
 
Changes in 
CT scan at 
14th day  
Group A 
n=35 
Group B 
n=35 
Total 
n=70 
Yes 4(11.4%) 13(37.1%) 17(24.3%) 
No 31(88.6%) 22(62.9%) 53(75.7%) 
Chi-Square= 6.29  p=0.012 
 
Table 5:Comparison of neurological outcome in 
term of suck reflex at the time of discharge 
between groups for age of neonates 
Age of 
neonate 
(hours) 
Suck 
Reflex  at 
discharge 
Group A 
n=35 
Group B 
n=35 
p-
Values 
2-3 hours 
Yes 
No 
Total 
12(70.6%) 
5(29.4%) 
17 
8(47.1%) 
9(52.9%) 
17 
0.16 
4-5 hours 
Yes 
No 
Total 
13(72.2%) 
5(27.8%) 
18 
6(33.3%) 
12(66.7%) 
18 
0.019 
 
Table 6:Comparison of neurological outcome in 
term of changes in CT scan at 14th day between 
groups  for age of neonates 
Age of 
neonates 
(hours) 
changes in 
CT  scan at 
14th day  
Group A 
n=35 
Group B 
n=35 
p-Values 
2-3 hours 
Yes 
No 
Total 
1(5.9%) 
16(94.1%) 
17 
7(41.2%) 
10(58.8%) 
17 
0.015 
4-5 hours 
Yes 
No 
Total 
3(16.7%) 
15(83.3%) 
18 
6(33.3%) 
12(66.7%) 
18 
0.248 
Table 7:Comparison of neurological outcome in 
term of suck reflex at the time of discharge 
between groups for male and female 
 
Age of 
neonate 
(hours) 
 
Suck Reflex 
 at 
discharge 
 
Group A 
n=35 
Group B 
n=35 
p-values 
Male 
Yes 
No 
Total 
16(69.6%) 
7(30.4%) 
23 
9(36%) 
16(64%) 
25 
0.02 
Female 
Yes 
No 
Total 
9(75%) 
3(25%) 
12 
5(50%) 
5(50%) 
10 
0.22 
 
Table 8:Comparison of neurological outcome in 
term of changes in CT scan at 14th day between 
groups for male and female 
Gender Changes in 
CT scan at 
14th day  
Group A 
n=35 
Group B 
n=35 
p-
Values 
Male 
Yes 
No 
Total 
3(13%) 
20(87%) 
23 
9(36%) 
16(64%) 
25 
0.06 
Female 
Yes 
No 
Total 
1(16.7%) 
11(83.3%) 
12 
4(40%) 
6(60%) 
10 
0.078 
Discussion 
Magnesium sulfate is neuroprotective because 
magnesium ions gate the NMDA receptor, thereby 
reducing the Calcium influx that can trigger cell 
death.[5] However, this block is voltage dependent and 
is overcome during the axonal  depolarization that 
occurs with hypoxic-ischemia. If the extracellular 
magnesium concentration is increased, then this 
blockade can be restored.6Present study demonstrates 
role of magnesium sulphate.  This was reflected by 
11.4% neonates with neurologic abnormalities and 
71.4% infants receiving oral feedings at discharge in 
the treatment group, which were significantly high as 
compared to control group. This is also supported by 
the neuroimaging results.  
Ichibia et al. conducted a multicenter, randomized, 
controlled trial to determine whether postnatal 
magnesium sulfate infusion (250 mg/kg/day) for 3 
days resulted in an improved outcome in babies with 
severe birth asphyxia. Enrolment criteria included a 5-
min APGAR score of 7 or less and either failure to 
initiate spontaneous respiration at 10 min after birth or 
occurrence of clinically apparent seizures within 24 h 
of birth. Survival with normal results on cranial CT, 
EEG and establishment of oral feeding by day 14 of 
age occurred significantly more often in neonates who 
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were given magnesium sulfate  as compared to control 
group. In the present study also, CT scan 
abnormalities occurred more frequently in the control 
group as compared to the magnesium group.6  
The protective role of magnesium sulfate has been 
based largely on studies with animal models, many of 
which showed favourable results in terms of 
amelioration of secondary neuronal injury.7 A few 
studies with pregnant women showed beneficial 
effects for neonates also. Nelson and Grether observed 
a lower incidence of cerebral palsy in preterm infants 
born to mothers who had received magnesium sulfate 
before delivery.8 Schendel et al and Grether et al 
observed the relationship of intrapartum magnesium 
sulfate administration to mothers and cerebral palsy in 
newborns. 7,9 They showed statistically significant 
effect of magnesium sulfate in preventing cerebral 
palsy. Harrison et al reported lower incidences of fetal 
heart rate deceleration and term stillbirths for mothers 
who received magnesium supplementation during 
pregnancy. There was no effect on the incidence of 
HIE, because it was an underpowered study and 
compliance was poor among the study population.10 
Some other studies have also shown that postnatal 
magnesium suphate infusion is effective in improving 
short term outcome in neonates with birth asphyxia.11-
13  
The role of magnesium sulfate in neuroprotection also 
is being evaluated in acute traumatic brain injury, in 
both adults and children. In a recent study, 
magnesium sulfate administration to children with 
severe traumatic brain injuries did not decrease 
cerebral perfusion pressure or mean arterial pressure 
and had no adverse effects on cardiac conduction.14 
Although one study in adults showed no beneficial 
effects of magnesium sulfate after traumatic brain 
injury.15  
Our study is the placebo-controlled trial that shows 
improved neurologic outcomes at discharge in the 
magnesium sulfate group. Good short term outcomes 
at discharge, the composite measure of all parameters, 
were statistically significant and individual 
components like neurologic abnormalities and oral 
feeding (sucking) were significant to support the 
positive role of magnesium sulfate infusion in 
improving the neurological outcome in term neonates 
with severe perinatal asphyxia. 
Conclusions 
Postnatal magnesium sulfate infusion is effective in 
improving outcomes for infants with severe perinatal 
asphyxia when it is given early (within 6 hours) and, 
in combination with other modalities of treatment 
during the therapeutic window.  
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